Boston Scientific Corp (BSX) stock price, news and key stats

Price

Last close as of Sep 16, 2026. Delayed data; not a live quote.

Previous close

$43.87

Open

$43.85

Day range

$43.65 – $44.67

Volume

24.9M

About Boston Scientific Corp

Latest BSX news

• Boston Scientific (BSX) Didn’t Miss on Demand or Devices. A Cyberattack Just Broke Its Guidance.
  Yahoo Finance · Sep 13, 2026

  Boston Scientific shares fell 2.3% in early trading Monday after the medical device maker disclosed that an August 25 cyberattack disrupted its manufacturing and shipping operations, forcing the company to withdraw caution on its near-term financial outlook. The company said the incident would have a "material impact" on third-quarter results, marking an unusual stumble for a business whose underlying demand and product performance remain intact. The attack, which Boston Scientific says affected production and distribution systems rather than demand for its devices, has prompted the company to stop short of reaffirming prior guidance. Management indicated that it expects to recover a portion of the impacted revenue as it works through order backlogs, but cautioned that the full financial effect remains uncertain. The company has resumed certain operations, though it has not disclosed whether any customer data was exfiltrated or whether its medical devices themselves were compromised. For investors, the episode presents a timing problem rather than a fundamental one, at least based on the company's early characterization. Revenue tied to procedures and device implants is often deferred rather than destroyed in supply disruptions, meaning some of the lost third-quarter sales could shift into later quarters as backlogs clear. Still, the uncertainty around the magnitude of the disruption—and the company's inability to quantify the damage—left the market with little to anchor expectations, contributing to the sell-off. The incident adds Boston Scientific to a growing list of healthcare companies grappling with cyber incidents that carry direct operational and financial consequences. With third-quarter results now clouded, investor attention will likely turn to updates on the pace of operational recovery, the durability of the order backlog, and whether the company provides a formal reset to guidance once the full scope of the disruption is known.

• In the News: Muer Yang on Private Equity’s Medical Device Push
  Private Equity · Sep 8, 2026

  Muer Yang, a prominent figure in the private equity sector, has recently highlighted the growing interest of private equity firms in the medical device industry. This trend is largely driven by the sector's potential for high returns, bolstered by an aging population and increasing demand for innovative healthcare solutions. Yang noted that private equity investments in medical devices have surged, as firms seek to capitalize on advancements in technology and the ongoing shift towards minimally invasive procedures. The implications for the market are significant. As private equity firms inject capital into medical device companies, there is potential for accelerated innovation and development of new products. This influx of funding can enhance competition within the industry, leading to improved patient outcomes and potentially lowering costs in the long term. However, it also raises concerns about the sustainability of such investments, particularly if firms prioritize short-term gains over long-term viability. Yang emphasized the importance of strategic partnerships between private equity firms and medical device manufacturers to navigate regulatory challenges and market dynamics effectively. As this trend continues, stakeholders across the healthcare spectrum will need to monitor the evolving landscape, as the intersection of private equity and medical devices could reshape the future of healthcare delivery.

• Boston Scientific says unlikely to meet 2026 sales, profit forecast after cyberattack
  Yahoo Finance · Sep 8, 2026

  Boston Scientific Corp. has announced that it is unlikely to meet its previously issued sales and profit forecasts for 2026 due to a significant cybersecurity incident that has disrupted its manufacturing and order shipments globally. The company, which specializes in medical devices, indicated that the fallout from the cyberattack will materially impact its financial performance for the third quarter and potentially beyond. This news has led to a sharp decline in the company's shares during premarket trading. Earlier this year, Boston Scientific had already reduced its growth target to a range of 5% to 6%. However, the recent cyberattack has raised concerns that even this adjusted forecast may be unattainable. The disruption in operations not only affects the company's ability to deliver products to customers but also raises questions about the overall resilience of its supply chain. Market analysts are now reassessing their outlook for Boston Scientific, which could have broader implications for investor sentiment in the medical technology sector as companies grapple with increasing cybersecurity threats.

• M&A Update: Is DME Still Attractive to Investors?
  IPO & M&A · Sep 4, 2026

  The durable medical equipment (DME) sector continues to draw attention from investors, despite recent fluctuations in the broader healthcare market. With an aging population and increasing demand for home healthcare solutions, DME companies are positioned to benefit from long-term growth trends. Recent mergers and acquisitions in the sector highlight ongoing interest, as firms seek to consolidate resources and expand their market reach. However, potential investors must navigate challenges such as regulatory scrutiny and reimbursement pressures that could impact profitability. The recent uptick in interest rates may also affect financing conditions for M&A deals, potentially slowing down transaction volumes. Analysts suggest that while the DME market remains attractive, investors should conduct thorough due diligence to assess individual company fundamentals and market positioning before committing capital. As the landscape evolves, strategic partnerships and innovative product offerings will likely play a crucial role in determining which companies emerge as leaders in the DME space.

• How better tail spend data can strengthen medical device compliance
  Yahoo Finance · Sep 1, 2026

  Medical device manufacturers are increasingly recognizing the importance of better tail spend data to enhance compliance and oversight of smaller suppliers not typically included in their main procurement programs. According to Oliver Norman, chief revenue officer at Nomia, a more granular understanding of tail spend can help manufacturers mitigate risks associated with regulatory compliance, quality control, and supply chain disruptions. This is particularly crucial in an industry where adherence to stringent regulations is paramount for maintaining market access and ensuring patient safety. The implications for the market are significant. As manufacturers adopt advanced analytics and data management strategies to track and evaluate tail spend, they can identify potential compliance issues before they escalate. This proactive approach not only strengthens regulatory adherence but also fosters stronger relationships with smaller suppliers, who often play a critical role in innovation and product development. By investing in better data management systems, medical device companies can enhance their operational efficiency and reduce the likelihood of costly recalls or regulatory fines, ultimately positioning themselves more favorably in a competitive landscape.

• Where Trump's tariffs hit Massachusetts the hardest
  Macro Watch · Sep 1, 2026

  President Donald Trump's recent implementation of sweeping tariffs is projected to have significant economic repercussions for Massachusetts, with the state facing a substantial financial burden. According to data from Trade Partnership Worldwide, the tariffs, which are expected to total $343 billion nationwide by June 2026, will disproportionately impact Massachusetts businesses and consumers. The state's economy, which relies heavily on imports and exports, could see increased costs for goods ranging from electronics to construction materials, potentially leading to higher prices for consumers and reduced profit margins for local businesses. The implications of these tariffs extend beyond immediate cost increases. Massachusetts, home to a robust manufacturing sector and a vibrant technology industry, may experience disruptions in supply chains as companies grapple with the added financial strain. Small businesses, in particular, have voiced concerns about their ability to absorb these costs, with many already facing challenges in a post-pandemic economy. The ongoing legal challenges to the tariffs, including a lawsuit filed by a coalition of 25 states, may further complicate the landscape, as businesses await clarity on the future of these trade policies. As the situation evolves, stakeholders in Massachusetts will need to closely monitor the effects of these tariffs on their operations and pricing strategies. The potential for retaliatory measures from trading partners could also exacerbate the economic fallout, making it crucial for businesses and policymakers to adapt to the changing trade environment.

• Self-Expanding Stents Market Outlook Highlights Strategic Opportunities Across The Industry
  Market Outlook · Aug 28, 2026

  The global self-expanding stents market is poised for significant growth, projected to increase from $4.51 billion in 2025 to $8.51 billion by 2034, reflecting a compound annual growth rate (CAGR) of 7.2%. This growth is driven by advancements in vascular intervention technologies, particularly the rising adoption of nitinol-based stents and a shift towards minimally invasive procedures. The expanding applications of self-expanding stents in peripheral interventions and the development of drug-compatible platforms are also key factors contributing to this upward trajectory. Emerging markets in the Asia Pacific region present substantial opportunities for market expansion, as healthcare systems increasingly recognize the benefits of self-expanding stents. The market dynamics in these regions are characterized by a growing demand for innovative medical devices that enhance patient outcomes and reduce recovery times. As healthcare providers seek to sustain long-term vessel openness, the emphasis on effective stent technologies is likely to intensify, further driving market growth. Overall, the self-expanding stents market is not only expanding in size but also evolving in its technological offerings, which could lead to increased competition among manufacturers. Companies that strategically position themselves to capitalize on these trends, particularly in emerging markets, may find lucrative opportunities in the coming years.

• Medtech M&A: choosing between private equity and strategic buyers
  Private Equity · Aug 27, 2026

  The medical technology (medtech) sector is experiencing a surge in mergers and acquisitions (M&A), with companies weighing the benefits of engaging private equity firms versus strategic buyers. Private equity firms are often drawn to medtech for their potential for high returns, leveraging financial engineering and operational improvements to enhance value. Conversely, strategic buyers, typically larger medtech companies, may offer synergies that can lead to accelerated growth and market expansion. As the landscape evolves, companies must consider their long-term goals when choosing between these two types of buyers. Private equity can provide the necessary capital and expertise to scale operations quickly, but may also impose a shorter investment horizon that prioritizes rapid returns. Strategic buyers, on the other hand, may be more patient and focused on integrating new technologies into their existing portfolios, potentially leading to more sustainable growth. Market implications are significant as the choice between these buyers can influence valuation metrics and deal structures. A preference for private equity could lead to increased competition for assets, driving up prices, while a strategic acquisition approach might foster a more collaborative environment, emphasizing innovation and product development. As the medtech sector continues to grow, understanding these dynamics will be crucial for stakeholders navigating this complex landscape.

• Skull Clamp Market Report 2026 Market Outlook Supported By A Forecast 10.2% CAGR
  Market Outlook · Aug 26, 2026

  The skull clamp market is projected to experience a robust growth trajectory, with a compound annual growth rate (CAGR) of 10.2% through 2026, according to the latest report from Market Outlook. This growth is primarily driven by the increasing prevalence of neurological disorders and the rising number of surgical procedures requiring precise cranial stabilization. The demand for advanced surgical equipment, particularly in neurosurgery, is expected to bolster market expansion as healthcare facilities prioritize patient safety and surgical accuracy. Geographically, North America is anticipated to dominate the skull clamp market, attributed to the presence of well-established healthcare infrastructure and significant investments in medical technology. However, the Asia-Pacific region is expected to witness the fastest growth, fueled by improving healthcare access and rising healthcare expenditures in emerging economies. As hospitals and surgical centers adopt innovative technologies, manufacturers are likely to focus on product development and strategic partnerships to enhance their market position. Market implications suggest that stakeholders should prepare for increased competition as new entrants emerge, particularly in regions with growing healthcare demands. Additionally, advancements in materials and design aimed at improving patient comfort and surgical outcomes may shape future product offerings. Overall, the skull clamp market presents lucrative opportunities for investors and companies willing to adapt to evolving healthcare needs.

• Medical device maker Boston Scientific is being hit by a cyberattack. The shares are falling
  CNBC Top News · Aug 26, 2026

  Boston Scientific is facing significant operational challenges following a cyberattack that has disrupted its global operations, including critical information systems necessary for processing and shipping customer orders. The company has not provided a timeline for when services will be restored, raising concerns among investors about potential revenue losses and customer dissatisfaction. As a result of the incident, Boston Scientific's shares have taken a hit, reflecting investor anxiety over the implications of the attack. The disruption could lead to delays in product deliveries, impacting relationships with healthcare providers and potentially affecting the company's market position in the competitive medical device sector. Analysts will be closely monitoring the situation, as prolonged operational issues could result in a reassessment of the company's earnings forecasts and overall financial health.

All 11 articles in the app →

Index membership

• S&P 500 · Health Care

Related Health Care stocks

• AAgilent Technologies
• ABBVAbbVie
• ABTAbbott Laboratories
• ALGNAlign Technology
• AMGNAmgen
• BAXBaxter International
• BDXBecton Dickinson
• BIIBBiogen